|
Market Closed -
NYSE
01:30:02 01/10/2026 am IST
|
5-day change | 1st Jan Change | ||
| 142.57 USD | -2.15% |
|
-0.10% | +3.41% |
| 30/09 | Merck's experimental skin disease drug succeeds in mid-stage study | RE |
| 30/09 | Major drugmakers turn to China for licensing deals | RE |
| Market Cap | 27TCr 24TCr 23TCr 21TCr 39TCr 26,20300Cr 39TCr 2,72800Cr 1,05000Cr 13,39500Cr 1,02600Cr 1,00400Cr 42,94600Cr | P/E 2026 * |
20.4x | P/E 2027 * | 17x |
|---|---|---|---|---|---|
| Enterprise Value | 30TCr 27TCr 25TCr 23TCr 43TCr 29,21700Cr 44TCr 3,04200Cr 1,17100Cr 14,93600Cr 1,14400Cr 1,11900Cr 47,88600Cr | EV / Sales 2026 * |
5.28x | EV / Sales 2027 * | 4.91x |
| Free-Float |
91.66% | Yield 2026 * |
3.03% | Yield 2027 * | 3.16% |
| Markets | Quality | ||
|---|---|---|---|
NYSE
| NVS | Delayed | |
CBOE
| NVS | Real-time | |
|
Tradegate
| NOTA | Real-time | |
|
London S.E.
| 0K9E | Delayed | |
|
Mexican S.E.
| NVS N | End-of-day quote | |
|
Deutsche Boerse AG
| NOTA | Delayed | |
|
Börse Stuttgart
| NOTA | Delayed | |
|
Boerse Muenchen
| NOTA | Real-time |
Last Transcript: Novartis AG
| 1 day | -2.15% | ||
| 1 week | -0.10% | ||
| 1 month | -6.24% | ||
| 3 months | -9.03% | ||
| 6 months | -6.66% | ||
| Current year | +3.41% |
| 1 week | 142.56 |  | 147.03 |
| 1 month | 137 | | 164.48 |
| Current year | 135.55 | | 170.46 |
| 1 year | 121.57 | | 170.46 |
| 3 years | 92.19 | | 170.46 |
| 5 years | 74.09 | | 170.46 |
| 10 years | 66.93 | | 170.46 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 50 | 01/02/2018 | |
Mukul Mehta
DFI | Director of Finance/CFO | - | 16/03/2026 |
Karen Hale
CMP | Compliance Officer | 58 | 14/04/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Nancy Andrews
BRD | Director/Board Member | 67 | 01/01/2015 |
| Director/Board Member | 69 | 01/01/2016 | |
Ton Büchner
BRD | Director/Board Member | 61 | 01/01/2016 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.15% | -0.10% | - | - | 28TCr | |
| -2.33% | +0.53% | +51.65% | +115.42% | 1,05600Cr | |
| -1.06% | -1.65% | +42.78% | +69.98% | 64TCr | |
| -0.65% | -1.32% | +12.98% | +75.49% | 47TCr | |
| -2.66% | -1.87% | +73.13% | +41.15% | 37TCr | |
| -0.06% | -3.88% | +34.32% | +39.39% | 34TCr | |
| -0.79% | +2.01% | +19.82% | +27.79% | 28TCr | |
| -1.19% | -1.21% | +9.82% | +10.61% | 25TCr | |
| -0.50% | +3.80% | +49.37% | +56.84% | 23TCr | |
| -1.47% | -1.53% | +34.28% | +98.89% | 19TCr | |
| Average | -0.97% | -0.18% | +36.46% | +59.51% | 42.4TCr | |
| Weighted average by Cap. | -1.10% | -0.23% | +39.91% | +71.39% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 5.77TCr 5.08TCr 4.81TCr 4.34TCr 8.19TCr 5,52900Cr 8.29TCr 58TCr 22TCr 2,82700Cr 22TCr 21TCr 9,06300Cr | 6.14TCr 5.41TCr 5.12TCr 4.63TCr 8.72TCr 5,89000Cr 8.83TCr 61TCr 24TCr 3,01100Cr 23TCr 23TCr 9,65300Cr |
| Net income | 1.42TCr 1.25TCr 1.19TCr 1.07TCr 2.02TCr 1,36200Cr 2.04TCr 14TCr 5.46TCr 70TCr 5.34TCr 5.22TCr 2,23300Cr | 1.58TCr 1.39TCr 1.32TCr 1.19TCr 2.24TCr 1,51300Cr 2.27TCr 16TCr 6.06TCr 77TCr 5.93TCr 5.8TCr 2,48000Cr |
| Net Debt | 3.14TCr 2.77TCr 2.62TCr 2.37TCr 4.46TCr 3,01400Cr 4.52TCr 31TCr 12TCr 1,54100Cr 12TCr 12TCr 4,94000Cr | 2.83TCr 2.49TCr 2.36TCr 2.13TCr 4.01TCr 2,71000Cr 4.06TCr 28TCr 11TCr 1,38500Cr 11TCr 10TCr 4,44100Cr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/26/30 | $142.57 | -2.15% | 30,61,982 |
| 29/26/29 | $145.71 | -0.80% | 15,98,808 |
| 28/26/28 | $146.88 | +0.98% | 19,49,456 |
| 25/26/25 | $145.46 | +1.32% | 11,65,774 |
| 24/26/24 | $143.57 | +0.60% | 18,87,688 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- NOVN Stock
- NVS Stock
Select your edition
All financial news and data tailored to specific country editions
